3. Duplicative Therapy

Concurrent administration of two or more topical calcineurin inhibitors does not provide enhanced therapeutic benefit and may result in additive adverse effects.  Concurrent administration of pimecrolimus cream and tacrolimus ointment is not recommended and will be reviewed.